Ipamorelin Research Peptide

Ipamorelin is a synthetic pentapeptide growth hormone secretagogue.

• Its sequence includes non-natural amino-acid residues designed to produce selective GH-releasing activity.
• Ipa is informal shorthand; Ipamorelin is distinct from GHRH analogues such as CJC-1295, Sermorelin, and Tesamorelin.

Ipamorelin acts through the growth hormone secretagogue, or ghrelin, receptor rather than the GHRH receptor.

• Early pharmacology found GH release with less ACTH and cortisol stimulation than several older GHRPs in tested animal models.
• A small human volunteer study characterized short-lived exposure and an episodic GH response.
• This category covers receptor differences, endocrine research, structure, storage, identity testing, and peptide comparisons.

Published human evidence is limited and largely early-stage pharmacokinetic or pharmacodynamic research.

• The available studies do not establish broad clinical effectiveness, long-term safety, or combination protocols.
• Ipamorelin is not generally approved as a therapeutic medicine, and research products require independent identity and quality verification.